Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
Cornell University · Weill Cornell Medicine · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
539
total citations
- FWCI
- 10.19
- Percentile
- 100%
- References
- 34
Citations per year
Authors
34- YHYuling HanCorresponding
Cornell University, Weill Cornell Medicine
- XDXiaohua Duan
Shanghai Jiao Tong University, Cornell University, State Key Laboratory of Oncogene and Related Genes, Weill Cornell Medicine
- LYLiuliu Yang
Cornell University, Weill Cornell Medicine
- BEBenjamin E. Nilsson-Payant
Icahn School of Medicine at Mount Sinai
- PWPengfei Wang
Aaron Diamond AIDS Research Center, Columbia University
Topics & keywords
Topics
Keywords
- Induced pluripotent stem cell
- Organoid
- Medicine
- Drug
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Coronavirus disease 2019 (COVID-19)
- Lung
- Pharmacology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ADAmerican Diabetes Association
- ISIcahn School of Medicine at Mount Sinai
- NNature
- NINational Institutes of HealthAwards: R01 DK124463, R01 DK116075-01A1, R01 DK119667-01A1, DP3 DK111907-01, 4R00CA226353, R01CA234614
- DADefense Advanced Research Projects AgencyAward: W911NF-16-C-0050
- WCWeill Cornell Medical College
- ARAdvanced Research Projects Agency
- NCNational Cancer InstituteAward: R01CA234614
- NINational Institute of Allergy and Infectious Diseases
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAwards: R01DK121072, R01 DK124463, R01 DK119667-01A1, 1RO3DK117252, DP3 DK111907-01, R01 DK116075-01A1